Avalo Therapeutics, Inc.·4

Mar 31, 4:09 PM ET

Chan Mitchell 4

Research Summary

AI-generated summary

Updated

Avalo (AVTX) Director Chan Mitchell Converts RSUs; Shares Withheld

What Happened

  • Chan Mitchell, a director of Avalo Therapeutics (AVTX), had a tranche of restricted stock units (RSUs) vest on March 28, 2026. The RSUs converted into 3,166 common shares. Those 3,166 shares were simultaneously surrendered/disposed (reported at $0.00), which indicates they were withheld to satisfy tax withholding obligations; no cash proceeds were reported.

Key Details

  • Transaction date: 2026-03-28; Form 4 filed 2026-03-31 (timely filing).
  • Reported activity: conversion/exercise of derivative (RSU conversion) — 3,166 shares acquired; 3,166 shares disposed at $0.00 (no cash proceeds).
  • Shares owned after transaction: not specified in the provided filing details.
  • Footnotes: F1 — RSUs convert 1-for-1 into common stock. F2 — The RSUs were part of a 9,500 RSU grant on Aug 13, 2024, vesting in thirds on Mar 28, 2025/2026/2027.
  • No indication of a 10b5-1 plan, gift, or sale for cash in this filing.

Context

  • This was a routine RSU vesting and conversion, not a market purchase or sale. The reported disposal at $0.00 is typically the company withholding shares to cover required taxes; the insider did not receive cash proceeds from these shares.
  • For retail investors: conversions/withholdings like this are common and usually administrative (tax-related) rather than a signal of buying or selling conviction.